May 28, 2025
Alcon announced the U.S. Food and Drug Administration (FDA) approved TRYPTYR® (acoltremon ophthalmic solution) 0,003%, formerly known as AR-15512, for the treatment of signs and symptoms of Dry Eye Disease.
“In clinical trials, I found the mechanism of action of this novel eye drop to be highly effective in stimulating TRPM8 receptors, which leads to reducing corneal pain while also increasing the eye’s natural tear production. I am honored to have worked on multiple clinical trials to help this new eye drop gain FDA approval, so it is available to my patients, and all dry eye sufferers”, said Guru R. Pattar, MD, PhD, Principal Investigator.
The eye drop will be available by prescription in single-use vials, one drop per eye, two times a day. It is expected to be available by the fall of 2025.
“This marks our 23rd FDA approval. Along with our sponsoring scientific research partners, including those in the pharmaceutical and biotechnology space, we have several new treatments pending before the FDA so there are many more announcements to come, as we are pleased to continue to offer new treatment options and to help improve human health through our Louisville, KY-based clinical trials site, Butchertown Clinical Trials,” said Mark Prussian, CEO and co-founder.
Butchertown Clinical Trials is an affiliate of The Eye Care Institute.
